Background Superficial bladder cancer accounts for 60%-70% of all bladder cancer cases in China, when treatment consists of only transurethral resection of the bladder tumor (TUR-BT) recurrence and progresses in the bladder are observed in some patients There are numerous reports of trials of intravesical instillation of anticancer agents with the objective of lowering this recurrence rate The aim of this study was to compare the prophylactic efficacy and safety of epirubicin (EPI), pirarubicin (THP) and hydroxycamptothecin (HCPT) in superficial bladder cancer Methods This study enrolled a total of 189 patients who had been diagnosed with superficial bladder cancer during the period from 2004 through 2007 at Beijing Friendship Hospital All patients were randomly allocated to one of three treatment groups Patients in group A received 29 doses of EPI 30 mg/30 ml, patients in group B received 29 doses of THP 30 mg/30 ml and patients in group C received 29 doses of HCPT 30 mg/30 ml, over a period of 24 months Results The recurrence-free rate in the 2 anthracycline treatment groups (A and B) were significantly better than that of the HCPT treatment group In the safety evaluation the incidences of pollakiuria pain on urination dysuria hematuria and contracted bladder were not significantly different between groups A and B but some were significantly higher in groups A and B than that in group C Conclusion The efficacy of EPI and THP was significantly better than HCPT in the prevention of bladder cancer recurrence